SCHEMBL5405409

SCHEMBL5405409

CCC[S+]([O-])c1ncc(/C(=C\C2CCCC2)C(=O)Nc2nccs2)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 5/20 0.49
EPHX2 P34913 1/20 0.41
POLB P06746 2/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
TSHR P16473 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HTT P42858 2/20 0.39
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
PKM P14618 1/20 0.38
LMNA P02545 2/20 0.37
USP2 O75604 1/20 0.37
MAPT P10636 1/20 0.37
STAT3 P40763 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5405425 1.00 GCK (0.49) GCKEPHX2POLBMEN1KMT2A
SCHEMBL5388861 0.86 GCK (0.45) GCKEPHX2POLBMEN1KMT2A
SCHEMBL2654881 0.86 GCK (0.45) GCKEPHX2POLBMEN1KMT2A
SCHEMBL2653417 0.82 GCK (0.53) GCKEPHX2POLBMEN1KMT2A
SCHEMBL2653423 0.82 GCK (0.53) GCKEPHX2POLBMEN1KMT2A
SCHEMBL2655201 0.81 GCK (0.48) GCKEPHX2POLBMEN1KMT2A
SCHEMBL2655198 0.81 GCK (0.48) GCKEPHX2POLBMEN1KMT2A
SCHEMBL2655116 0.79 GCK (0.55) GCKEPHX2POLBMEN1KMT2A
SCHEMBL2655114 0.79 GCK (0.55) GCKEPHX2POLBMEN1KMT2A
SCHEMBL14423913 0.78 GCK (0.51) GCKEPHX2POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262196-B2 Tri(cyclo) substituted amide glucokinase activator compounds PROSIDION LIMITED (GB) 2007-08-28 US claimed
US-20040186290-A1 Tri(cyclo) substituted amide glucokinase activator compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US claimed
US-7262196-B2 Tri(cyclo) substituted amide glucokinase activator compounds PROSIDION LIMITED (GB) 2007-08-28 US disclosed
US-7262196-B2 Tri(cyclo) substituted amide glucokinase activator compounds PROSIDION LIMITED (GB) 2007-08-28 US disclosed
US-7262196-B2 Tri(cyclo) substituted amide glucokinase activator compounds PROSIDION LIMITED (GB) 2007-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186290-A1 Tri(cyclo) substituted amide glucokinase activator compounds GCKR, GCK, GALK1 GCK 2/4885EPHX2 4155/4885POLB 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.